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Background: Population-based studies on childhood community-acquired pneumonia are scarce
in Latin America. Pneumococcal epidemiology is poorly defined, hence the World Health
Organization recommended standardized chest radiograph interpretation to improve the
approach to bacterial pneumonia. Therefore, our study aimed to estimate the burden of
pneumonia in hospitalized children.
Methods: A three-year surveillance study was carried out in four hospitals covering a population
of 229 128 inhabitants of whom 10.2% were under five years of age. Clinical records and
digitization of their chest radiographs were obtained. A pediatrician and a pediatric radiologist
blinded to the clinical diagnosis interpreted the digital images.
Results: Of 2034 patients, 826 (40.6%) had consolidated pneumonia, 941 (46.3%) had non-
consolidated pneumonia, and 267 (13.1%) had no pneumonia. Children under two years of age
predominated (66.9%). The average annual incidence rate for consolidated pneumonia over the
three-year study period was 1175/105. Eighteen invasive Streptococcus pneumoniae were
isolated from patients with consolidated pneumonia and two from those with non-consolidated
pneumonia. Respiratory syncytial virus was evenly distributed between both X-ray groups.
Conclusions: Patients younger than two years of age predominated, being the main targets for
anti-pneumococcal conjugated vaccines. Incidence rates provided evidence of the burden of
consolidated pneumonia for childhood, estimating the potential benefits of vaccination.
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Pneumonia is themajor cause ofmorbidity andmortality from
pneumococcal infection, especially in developing countries.1
Population-based studies on community-acquired pneumoniaPublished by Elsevier Ltd. All rights reserved.
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Table 1 Age distribution of children aged less than five
years hospitalized with community-acquired pneumonia
Age (in months) Cases (n) % Accum. %
0—5 381 18.7 18.7
6—11 399 19.6 38.3
12—23 581 28.6 66.9
24—35 312 15.3 82.2
36—59 361 17.8 100.0
Total 2034 100.0in childhood are scarce in Latin America and Streptococcus
pneumoniae epidemiology is poorly defined due to the low
sensitivity of bacteriologic diagnostic methods. To overcome
this problem the World Health Organization (WHO) recom-
mended standardized chest radiograph interpretation as an
epidemiological tool to provide a reasonable approach to
bacterial pneumonia.2 In addition, to assure comparability
of data among population-based studies on pneumonia burden
and results from vaccine field trials performed in different
countries, a generic protocol was proposed by the WHO in
collaboration with the Communicable Disease Center (CDC).
This protocolwas adopted in several Latin American countries,
including Uruguay, in order to assess the burden of consoli-
dated pneumonia in hospitalized children under five years of
age, and the proportion preventable by vaccination with a S.
pneumoniae conjugated vaccine.3 In Uruguay, this estimation
was facilitated because ten years of anti-Haemophilus influ-
enzae typeb (Hib) vaccination had dramatically controlledHib
pneumonia, and consequently it was possible to assume that
most of the remaining bacterial pneumonia cases were due to
S. pneumoniae.4,5 Also, bacteremic pneumonia has beenmon-
itored since 1994, providing data on serotype frequency and
antibiotic susceptibility of invasive isolates.6,7
Methods
A three-year population-based prospective study (June
2001—May 2004) was carried out in the municipalities of
Paysandu´ and Salto in Uruguay, covering a population of
229 128 inhabitants of whom 23 445 (10.2%) were under five
years of age. These populations represent 7.1% and 8.3% of
the total national population, respectively.
Patients were enrolled in four hospitals (two public and
two private). Those eligible for enrollment were patients
with acute lower respiratory tract infections for whom a
chest X-ray was performed on admission to confirm a clini-
cally suspected case of pneumonia. Excluded from the study
were bronchiolitis and asthma/bronchial hypersensitivity
cases for whom no X-ray was ordered.
A research nurse checked the pediatric ward admission
book daily looking for children under five years of age. The
medical charts of the patients were reviewed and relevant
data were abstracted onto a standardized form including
age, sex, previous hospitalizations, recent antibiotic-treated
episodes, underlying conditions, selected respiratory signs
and symptoms, antibiotherapy, duration of hospitalization,
and outcome.
Digitization of the analog chest X-rays was also per-
formed. A pediatrician and a pediatric radiologist, blinded
to the patients’ clinical diagnoses, interpreted the digital
images according to the WHO criteria: alveolar consolidation
or pleural effusion, non-consolidated pneumonia with mild
interstitial/perihilar changes, and no pneumonia. By a table
of random numbers, 10% of the digitized chest X-rays were
identified and referred to an international panel of experts
for quality evaluation.
Selected variables from the standardized form were com-
pared between children with consolidated and non-consoli-
dated pneumonia.
Bacterial and viral etiologies were routinely investigated
during three winter months, three days per week. During the
three study years, blood or pleural fluid specimens werecultured by standard methods for isolation of invasive pneu-
mococci. At the National Reference Laboratory, identifica-
tion of S. pneumoniae isolates was confirmed, serotypes
determined by ‘quelling’ reaction, and susceptibility to
antibiotics (penicillin, third generation cephalosporins, tri-
methoprim—sulfamethoxazole, vancomycin) assessed
according to the National Committee for Clinical Laboratory
Standards. Viral antigens for five respiratory viruses (respira-
tory syncytial virus (RSV), influenza A and B, parainfluenza 3,
and adenovirus) were investigated by direct immunofluores-
cence (Light Diagnostics, Respiratory Panel, CA, USA) in cells
of nasopharyngeal aspirates during the last two study years.
Data were entered into Epi Info 6.4, which was also
employed for statistical analysis.
To calculate the annual incidence rate of chest X-ray
documented consolidated pneumonia cases, the number of
cases enrolled in one year (numerator), was divided by the
number of population at risk in the area (denominator), and
the result multiplied by 100 000. Non-parametric variables
were evaluated by Chi-square test and results were consid-
ered significant when p < 0.05. The kappa coefficient was
used to measure the degree of agreement between the
interpretation of the local readers and the reference panel
of experts. This project was approved by the Pediatric
Committee of Ethics from the Pediatric Institut Prof L.A.
Morquio.
Results
Between June 2001 andMay 2004, 2034 childrenwere eligible
for enrollment: 668, 662, and 704 patients per year. The
majority of the inpatients were cared for at public hospitals,
while a minority were admitted to private services, 97.1%
and 2.9%, respectively. Most of the families lived in urban
areas (82.2%), but their homes were located in areas where
dwelling conditions and poverty predisposed the children to
illness. Only 363 patients lived in rural areas (17.8%).
Table 1 shows the age distribution of all the enrolled
patients. Of these 54.5% were male. Their median age was
one year (range 0—4) with predominately children younger
than 24 months (66.9%), of whom 38.3% were aged less than
12 months.
The standardized radiograph interpretation of 2034
patients indicated that 826 (40.6%) had consolidated pneu-
monia, 941 (46.3%) had non-consolidated pneumonia, and
267 (13.1%) had no pneumonia. Agreement between the
interpretation of the local readers and those of the panel
of experts showed a kappa coefficient of 0.58, which vali-
dated the study results.
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Table 2 Total enrolled cases, consolidated pneumonia, and non-consolidated pneumonia by age of the patients
Age (months) Cases (n) CP (n) % Empyema (n) Non-CP (n) % No P (n) %
0—5 381 110 28.9 4 185 48.6 86 22.5
6—11 399 143 35.8 7 203 50.9 53 13.3
12—23 581 266 45.8 15 273 47.0 42 7.2
24—35 312 140 44.9 16 132 42.3 40 12.8
35—59 361 167 46.3 12 148 40.9 46 12.8
Total 2034 826 40.6 54 941 46.3 267 13.1
CP, consolidated pneumonia; non-CP, non-consolidated pneumonia; no P, no pneumonia.Table 2 presents the age distribution of consolidated and
non-consolidated pneumonia cases: the number of consoli-
dated pneumonia cases increased with age, as did complica-
tions (54 cases with empyema; 6.5%), while non-consolidated
pneumonia predominated in patients aged 0—11 months.
Although incidence rates of consolidated pneumonia var-
ied annually, its variation was not statistically significant. As
shown in Table 3, incidence rates changed according to age
group. In every surveillance year, the highest incidence rates
were recorded among patients aged less than 24 months,
predominately in the 12—23 months age group.
Of 462 blood or pleural effusion cultures, 20 S. pneumo-





2nd line antibiotica 60/826 7.3
White blood cell countb 346/826 41.9
Hospitalization durationc 317/826 38.4
Days in intensive cared 17/826 2.1
Bacteremic pneumoniae 18/273 6.6
a Third generation cephalosporins or/and vancomycin.
b WBC count >15  109 cells/L.
c Hospitalization duration >5 days.
d Intensive care >6 days.
e Streptococcus pneumoniae isolated from blood or pleural effusion
Table 3 Incidence rates of consolidated pneumonia in children b
Age (months) Population at riska Period
Jun 01—May 02
Freq. CP Rate/10
0—11b 4786 81 1692
12—23 4610 81 1757
24—35 4825 48 995
36—59 9224 50 542
Total 23 445 260 1109
CP, consolidated pneumonia.
a National Statistic Institute (INE), 1996 Census.
b INE do not provide separate data for 0—5 and 6—11 months.teen of the isolates corresponded to patients with
consolidated pneumonia, and two to non-consolidated pneu-
monia patients. Eleven isolates were available for typing and
for antibiotic susceptibility testing. Nine were serotype 14
with reduced susceptibility to penicillin (1.0 mg/mL) and to
trimethoprim—sulfamethoxazole; one was serotype 5 and
one was 18C, both susceptible to penicillin.
Viral antigens were recognized in 81 out of 228 nasophar-
yngeal aspirates (35.5%). The percentages of viral detection
were similar in both radiographic groups: 38 RSV, three
influenza A and one influenza B in consolidated pneumonia
cases (18.4%) and 36 RSV, two parainfluenza 3, and one












y age group and study years
Jun 02—May 03 Jun 03—May 04
5 Freq. CP Rate/105 Freq. CP Rate/105
84 1755 88 1839
93 2017 92 1996
51 1057 41 850
68 737 49 531
296 1263 270 1152
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which malnutrition and anemia was the most prevalent
(409; 53.0%), followed by asthma/bronchial hypersensitivity
(164; 21.3%) and neurologic disabilities (94; 12.2%).
Severity of the cases was evaluated comparing six vari-
ables as recorded among patients with consolidated and non-
consolidated pneumonia (Table 4). Second line antibiotic
therapy, white blood cell count above 15  109/L, and inva-
sive S. pneumoniae isolation predominated among patients
with consolidated pneumonia ( p < 0.05).
Six children died: five were aged under 12 months and one
belonged to the 2—4 year-old age group. Co-morbidity was
present in four of the fatalities (one asthma and three
cerebral palsy) and five of the patients had consolidated
pneumonia.
Discussion
Awareness of the health impact of pneumonia in childhood is
of paramount importance in the decision-making for its
prevention. This disease is rarely mentioned by national
sanitary authorities as a health problem, although a recent
publication confirmed that 19% of deaths in children under
five years of age are due to pneumonia.8 Consequently, the
problem became a priority for the Division of Vaccines and
Immunization of the Pan American Health Organization
(PAHO), in order to prepare for the introduction of an appro-
priate conjugate vaccine to reduce pneumococcal mortality
and severe morbidity in children younger than five years of
age. Efforts were addressed to collect population-based data
on the burden of pneumonia in children from the region.
Research was based on the WHO generic protocol, and sup-
ported by PAHO in Argentina, Brazil, and Uruguay, and spon-
sored by the industry in Argentina (Co´rdoba) and in Chile
(Santiago). A radiographic marker suggestive of bacterial
pneumonia was advocated, similar to the one used in con-
jugated vaccine trials for evaluating the efficacy of anti-S.
pneumoniae conjugate vaccines.9,10
Uruguay has also contributed, building a three-year evi-
dence base on the burden of consolidated pneumonia in
Paysandu´ and Salto. Patients under two years of age pre-
dominated (66.9%), pointing to the urgent need for a nine-
valent conjugate vaccine that would provide a coverage of
78% for pneumonia in these children. This coverage would
increase by 10% if serologic cross-reactivity with serotypes
included in the vaccine were taken into account.11,12
This study enabled us to estimate annual incidence rates
for different age groups that represented 8.3% of the national
population aged 0—59 months. The highest annual incidence
rates of consolidated pneumonia ranged from 1757/105/year
to 2017/105/year among patients aged 12—23 months, con-
firming the need to protect them. The PAHO-supported study
recorded similar incidence rates in Argentina (Pilar, Buenos
Aires, and Concordia, Entre Rı´os).13 Also based on the WHO
generic protocol, studies from Chile and Brazil showed lower
incidence rates. In Santiago the rate was 928/105/year and in
Goiania patients aged 0—23 months the incidence rate was
758/105/year.14
As patients with consolidated pneumonia, and those cases
complicated with empyema increased with age, potential
limitations to the vaccine effectiveness could occur as opti-
mal results were obtained for children under 24 months ofage.15 Therefore, children with risk factors, aged 2—14 years,
could benefit from the 23-valent S. pneumoniae polysacchar-
ide vaccine.16,17
Etiological information on pneumonia cases has provided
some valuable insights. Invasive S. pneumoniae isolation has
mainly been achieved in patients with presumed bacterial
pneumonia.18 The almost even distribution of the viral etiol-
ogies among patients with consolidated and non-consoli-
dated pneumonia could be explained by the increasing
recognition of mixed infections, due to co-circulation of
respiratory viruses and S. pneumoniae as well as other
non-investigated bacterial pathogens.19—22
This study aimed to establish the local burden of pneu-
mococcal disease and to assess the potential vaccine impact
to justify its introduction in Uruguay. Nevertheless the
results shown only include hospitalized cases. Meningitis
and other invasive pneumococcal diseases should also be
considered; even if they are quantitatively less relevant
they involve high mortality and sequelae.23 Ambulatory
treated pneumococcal cases as well as pneumococcal dis-
eases in school-aged children cannot be ignored when pre-
dicting the effectiveness of a vaccine.24 As 46.6% of the
enrolled patients belonged to families in poverty, and socio-
economic improvements are difficult to achieve in a short
period of time, vaccination appears to be the best measure
for health equity.25,26 Thus high priority should be given to
the development of an affordable pneumococcal conjugate
vaccine suitable for the protection of Latin American chil-
dren.
In spite of the limitations of this study, the information
obtained is valuable because it provides much-needed popu-
lation-based data for Uruguay. Besides enhancing the efforts
of multidisciplinary groups, a surveillance network has been
developed that is able to generate scientific evidence to
support decisions concerning the use of vaccines to control
pneumonia and other invasive diseases, and to evaluate the
impact of vaccination programs.
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